Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct;20(10):1348-1359.
doi: 10.1200/OP.23.00794. Epub 2024 May 15.

Breast Cancer Brain Metastasis: A Comprehensive Review

Akshara S Raghavendra  1 , Nuhad K Ibrahim  1
Affiliations
Review

Breast Cancer Brain Metastasis: A Comprehensive Review

Akshara S Raghavendra et al. JCO Oncol Pract. 2024 Oct.

Abstract

The mechanisms underlying breast cancer brain metastasis (BCBM) development are complex, and its clinical presentation varies depending on the number, location, and size of brain metastases. Common symptoms include headache, neurologic deficits, and seizures. Diagnosis of BCBM typically relies on neuroimaging techniques, such as magnetic resonance imaging and computed tomography scans. Local therapies, such as surgery and stereotactic radiosurgery, can be used to control tumor growth and relieve symptoms. Whole-brain radiotherapy has been a mainstay of treatment for BCBM, but its use has been associated with cognitive decline. Systemic therapy with chemotherapy and targeted agents plays an increasingly important role in the management of BCBM. Novel agents, such as human epidermal growth factor receptor 2 (HER2)-targeted therapies and tyrosine kinase inhibitors, have shown promising results in improving survival for patients with HER2-positive and triple-negative BCBM. This comprehensive review synthesizes current knowledge, clinical insights, and evolving paradigms to provide a robust understanding and roadmap for optimizing the diagnosis and management of BCBM.

PubMed Disclaimer

Conflict of interest statement

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

No potential conflicts of interest were reported.

References

    1. Darlix A, Louvel G, Fraisse J, et al. : Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort. Br J Cancer 121:991-1000, 2019 - PMC - PubMed
    1. Hardesty DA, Nakaji P: The current and future treatment of brain metastases. Front Surg 3:30, 2016 - PMC - PubMed
    1. Witzel I, Oliveira-Ferrer L, Pantel K, et al. : Breast cancer brain metastases: Biology and new clinical perspectives. Breast Cancer Res 18:8, 2016 - PMC - PubMed
    1. Reference deleted.
    1. Bailleux C, Eberst L, Bachelot T: Treatment strategies for breast cancer brain metastases. Br J Cancer 124:142-155, 2021 - PMC - PubMed